Article: Genentech.(Update)(increased risk of severe arterial thromboembolic events)(Brief Article)

Genentech said there is evidence of an increased risk of severe arterial thromboembolic events related to the use of its Avastin (bevacizumab). In a letter released by the FDA in August, the company cited an ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!